Core Viewpoint - McKesson has raised its profit forecast, focusing on high-margin businesses like cancer medicines to drive growth [1] Company Summary - McKesson is a U.S. drug distributor that is shifting its strategy towards high-margin sectors to enhance profitability [1]

Group 1 - McKesson will restructure its operations into four main segments starting from the current quarter [1] - The restructuring aims to focus on high-margin businesses, particularly cancer medicines, to enhance growth [1]

Financial Performance - AstraZeneca reports better-than-expected sales [1] - AstraZeneca's profit is rising for the second quarter [1] Product Performance - Growth is spurred by its stable of cancer medicines [1]